Related Experiment Videos
Encephalopathy in scleromyxedema
K Johkura1, K Susuki, O Hasegawa
1Department of Neurology, Urafune Hospital, Yokohama City University, Yokohama, Japan.
Abstract:
The authors monitored CSF findings for over 5 months in a patient with a fatal case of scleromyxedema and two episodes of encephalopathy. During both encephalopathy episodes, CSF protein and immunoglobulin G (IgG) levels were elevated without an increased IgG index or IgG synthesis rate. A CSF-dominant increase in the concentration of interleukin-6 (IL-6) also was noted during encephalopathy. These findings suggest a disruption of the blood-brain barrier and that IL-6 may play some role in mediating the encephalopathy. OFF
Insights
Scleromyxedema encephalopathy involves elevated cerebrospinal fluid (CSF) protein and immunoglobulin G (IgG) during episodes. Interleukin-6 (IL-6) may play a role in this neurological complication.
Area of Science:
- Neurology
- Immunology
- Dermatology
Background:
- Scleromyxedema is a rare, chronic autoimmune disease characterized by excessive deposition of mucin in the dermis.
- Encephalopathy is a serious neurological complication that can occur in patients with scleromyxedema, but its underlying mechanisms are not fully understood.
Observation:
- Cerebrospinal fluid (CSF) was monitored for over 5 months in a patient with fatal scleromyxedema experiencing two episodes of encephalopathy.
- During both encephalopathy episodes, CSF analysis revealed elevated total protein and immunoglobulin G (IgG) levels.
Findings:
- Despite elevated CSF protein and IgG, the IgG index and IgG synthesis rate remained normal, suggesting a localized intrathecal process.
- A significant, CSF-dominant increase in interleukin-6 (IL-6) concentration was observed specifically during the encephalopathy episodes.
- These findings indicate a potential disruption of the blood-brain barrier during encephalopathy.
Implications:
- The data suggest that elevated IL-6 in the CSF may be a key mediator in the pathogenesis of encephalopathy associated with scleromyxedema.
- Understanding these mechanisms could lead to targeted therapies for neurological complications in rare autoimmune diseases.
- Further research is warranted to elucidate the precise role of IL-6 and blood-brain barrier integrity in scleromyxedema-related encephalopathy.